EyePoint (EYPT) Interest & Investment Income (2010 - 2026)
EyePoint (EYPT) posted Interest & Investment Income of -$159000.0 for Q1 2026, down 478.57% sequentially from $42000.0 in Q4 2025, and down 51.43% YoY from -$327352.9 in Q1 2025.
Powered by 
Analysis
EyePoint (EYPT) Interest & Investment Income (2010 - 2026) Analysis & Trends
EyePoint has reported Interest & Investment Income for 13 years, with the latest figure at -$159000.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 51.43% year-over-year to -$159000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$121000.0 (down 239.08% YoY) and the FY2025 annual result came in at -$67000.0, down 140.85% from the prior year.
- Interest & Investment Income retreated to -$159000.0 in Q1 2026 per EYPT's latest filing, from $42000.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $379000.0 in Q3 2024 and troughed at -$186000.0 in Q2 2022.
- A 5-year average of -$2294.1 and a median of -$1000.0 in 2023 frame the typical range for Interest & Investment Income.
- The widest YoY moves for Interest & Investment Income: up 38000.0% in 2024, down 4300.0% in 2024.
- Over 5 years, Interest & Investment Income stood at $133000.0 in 2022, then sank by 82.71% to $23000.0 in 2023, then sank by 721.74% to -$143000.0 in 2024, then soared by 129.37% to $42000.0 in 2025, then tumbled by 478.57% to -$159000.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered -$159000.0, $42000.0, and $87000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | -9,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -9,000.00 |
| Mar 31, 2026 | -159,000.00 |
| Dec 31, 2025 | 42,000.00 |
| Sep 30, 2025 | 87,000.00 |
| Jun 30, 2025 | -91,000.00 |
| Mar 31, 2025 | -105,000.00 |
| Dec 31, 2024 | -143,000.00 |
| Sep 30, 2024 | 379,000.00 |
| Jun 30, 2024 | -44,000.00 |
| Mar 31, 2024 | -28,000.00 |
| Dec 31, 2023 | 23,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -1,000.00 |
| Mar 31, 2023 | 57,000.00 |
| Dec 31, 2022 | 133,000.00 |
| Sep 30, 2022 | 51,000.00 |
| Jun 30, 2022 | -186,000.00 |
| Mar 31, 2022 | -53,000.00 |
| Mar 31, 2017 | 1,000.00 |
| Sep 30, 2016 | 1,000.00 |